PRESS RELEASE

oresa ventures s.a. (publ)

Interim report for the nine months to 30 september 1999

- Profit after tax for the 9 months of USDM 2.7 (SEKM 22.0), equivalent to USD 0.28 (SEK 2.27) per share.
- Net Asset Value USDM 64.15, equivalent to USD 6.61 (SEK 53.87) per share.
- -90% of total assets, or USDM 65.47, in Direct Investments.
- 61% of Direct Investments in Poland.
- A successful offer to acquire the outstanding minority shares in Medicover initiated during the quarter.
- In its core market in Poland, Medicover reached an important milestone, by recording a profit in September, as membership continues to grow significantly.
- Continued strong performance in the portfolio companies, and especially Brewery Holdings Ltd., which in October recorded a fifth consecutive month as market leader in Romania.

The results for the 9 months to 30 September 1999 show a profit after tax of USDM 2.7 (SEKM 22.0). Our Net Asset Value amounted to USD 6.61 (SEK 53.87) per share, up from USD 6.39 (SEK 51.40) at the start of the year.

The third quarter recorded an after tax loss of USDM 0.98. The loss was driven primarily by a drop of approximately USDM 0.500 in the value of the remaining Russian listed shares, which we are liquidating as trading conditions allow. Operating expenses for the quarter were in line with budget at USDM 0.59.

In line with our policy, we cover existing investments in our 6 and 12 months reporting and in the 3 and 9 month reports we cover new investments, as well as any events of particular importance in existing holdings.

During the quarter, we made no investments in new companies. The additional investment of USDM 2.0 in Office Depot, which was also mentioned in the 6 month report, has been finalized and the transaction, through which Office Depot acquired the Office Centre chain from DIVACO of Germany, has received regulatory clearance in Poland.

As we communicated to all our shareholders on 15 September, we are increasing our ownership in Medicover, the healthcare company which is our largest investment. During the quarter, we reached an agreement with the largest minority shareholders in Medicover, the British fund manager Taube-Hodson-Stonex Partners (THS Partners), to acquire all of their clients' shares in Medicover. We also extended an offer on the same terms and conditions to all of the other minority

shareholders in Medicover. Through the offer, which was completed after the end of the reporting period, ORESA Ventures controls 95%* of the issued shares in Medicover.

Payment for the shares will be through new shares to be issued in ORESA Ventures. Through the transaction, valued at USDM 11.75, the number of ORESA Ventures shares outstanding will increase by 2,053,998 shares to a total of 11,753,281 shares. The Net Asset Value will increase to USDM 75.91, equivalent to USD 6.46 per share. We believe the dilution of 2.3% in the Net Asset Value per share resulting from the transaction, is more than compensated by the potential for strong growth in the value of the shares acquired. The rationale for the transaction is the expected strong growth in the market for private healthcare in Poland and throughout the Region and Medicover's unique market position and well established brand name. By acquiring additional shares in Medicover, we are in a better position to control and accommodate a future strategic exit transaction. Through the acquisition, THS-Partners becomes the third largest shareholder in ORESA Ventures, with approximately 10% of the company. THS-Partners is a well-reputed, London-based fund manager with more than GBP 2 billion under management and I would like to welcome them as shareholders in ORESA Ventures.

Equity investments excluding loan investments

		Owner-	Cost	Valuation	% of	
Country3	Company	ship, %	USDM	USDM	NAV	
Poland	Medicover2	68.2	15.4	28.7	44.7	
	Office Depot	t 7. 4	5.5	5.5	8.6	
	Bev. H. Vide	eo	22.5	4.5	4.5	7.0
	United Entert	t .	37.0	5.0	5.0	7.8
	Intersource	16.0	0.5	0.5	0.8	
	Subtotal		30.9	44.2	68.9	
Czech Rep.	Droxi	12.2	3.4	3.4	5.3	
Bulgaria		_	0.5	0.5	0.8	
Baltics	Airo	23.0	1.5	1.5	2.3	
Romania	Flanco	58.0	1.0	1.0	1.6	
	Churchill	26.0	0.7	0.7	1.1	
	BHL	1	2.6	2.6	4.1	
	Motoractive	47.5	0.6	0.6	0.9	
	Various	_	0.5	0.5	0.8	
	Subtotal		5.4	5.4	8.5	
Russia	Invacorp	4.1	2.0	1.4	2.2	
	RIG	4.0	2.6	1.3	2.0	
	Subtotal		4.6	2.7	4.2	
Funds	Fulcrum	2.8	2.3	2.7	4.2	
	Ukraine Fund	12.1	0.3	0.3	0.5	
	Danube Fund	1 2.2	0.2	0.2	0.3	
	EMESCO	_	0.7	0.7	1.1	
	Subtotal	7.1	3.5	3.9	6.1	
	Total		49.8	61.6	96.1	
4 3 7 . 11 1	•					

¹ Not disclosed.

^{* 91.2%} on a fully diluted basis from approved Medicover management option programs.

² As a subsequent event, ORESA Ventures has aquired an additional 2.35m shares in Medicover, raising the total investment in Medicover to 95%, with cost USDM 27.15 and valuation USDM 40.45.

3 The geographical analysis in this table is based on the primary location of the business.

MEDICOVER

Medicover continued to develop well during the quarter. Total enrollment in all programs increased by more than 6,000 to an excess of 44,000. We feel confident that the stated year-end target of close to 50,000 lives covered can be reached.

Sales for the 9 months stood at USDM 9.6, representing an increase of 48% compared with the same period last year.

EBITDA loss for the 9 months came in at USDM 2.1. The Group is expected to turn profitable on a monthly EBITDA basis during the fourth quarter. The revenue and financial results for the Group show an approximate 3 month time-lag versus budget.

Of significant importance, is the fact that the key Polish market, which represents some 75% of Group revenue, turned profitable in September. Polish revenue in September stood at just below USDM 1.0 and posted a modest positive EBITDA of USD 11,000. This is a combination of Warsaw revenue with good profitability and the Polish regions, where most operations are less than 18 months old and are still generating deficits. However, reaching the point where Poland as a country operation is profitable is a milestone, as each new enrolled member will provide a good bottom-line contribution.

The study we are undertaking together with an international consultancy firm, which we have previously described and which aims to identify 3-4 new growth areas within the healthcare service sector, has estimated the size of the Polish market for private health insurance to be USD 3 billion by 2005. The market is, therefore, expected to grow strongly and Medicover is committed to develop a significant market share.

OUTLOOK

At the end of the third quarter, we had available financial resources of USDM 10, including committed credit facilities and the remaining portfolio of primarily Russian listed shares. The work with the consultancy firm referred to above has recently been finalized for the Polish market and a second phase, studying the opportunities in Hungary and the Czech Republic, will now start. We believe the findings are encouraging and will result in several new projects. The initiative during the quarter from the new European Commission and its President, Mr. Prodi, to speed up the application process into the European Union for the Central and East European countries, evidences the political will and support for integrating the economies in Central and Eastern Europe into the European Union. This validates our strong belief in the long-term growth potential of the countries in which ORESA Ventures invests.

Jonas af Jochnick November 1999

CONSOLIDATED PROFIT AND LOSS ACCOUNT

Qrt 3 to	Qrt 3 to	9 Months	9 Months		
30 Sept	30 Sept	to 30 Sept	to 30 Sept		
1999	1998	1999	1998		
QUARTER 3 TO 30 S	EPTEMBER	\$'000	\$'000	\$'000	\$'000

Portfolio income/(loss)	(479)	(27,664)	4,723	(38,482)	
Interest income	45	112	111	2,064	
Interest cost (130)	(14)	(321)	(23)		
Dividend income	19	245	102	348	
Other revenue	83	69	264	213	
INCOME (462)	(27,252)	4,879	(35,880)		
Staff costs (365)	(463)	(1,112)	(1,462)		
Administrative costs	(220)	(351)	(1,064)	(1,241)	
Foreign exchange	(4)	(20)	5	(47)	
OPERATING EXPENSES	(589)	(834)	(2,171)	(2,750)	
OPERATING PROFIT/(LC (38,630)	OSS) BEFOR	E TAX	(1,051)	(28,086)	2,708
Tax (charge)/income	71	(87)	(3)	221	
OPERATING PROFIT/(LC (38,409)	OSS) AFTER	` /	(980)	(28,173)	2,705
		(4.5		(4.5.5.5)	
Earnings/(loss) per share	(\$0.10)	(\$2.90)	\$0.28	(\$3.96)	

STATEMENT OF RECOGNISED GAINS AND LOSSES

	Qrt 3 to 30 Sept 1999 \$'000	20 Sept 1998 \$'000	9 Months to 30 Sept 1999 \$'000	9 Months to 30 Sept 1998 \$'000		
Direct Inv	ustments upward estments, not rec and loss account	s on unlisted cognised in	(662)	_	12,603	
` /	ofit for the year egnised gains/(lo	(980) sses)	(28,173) (980)	2,705 (28,835)	(38,409) 2,705	(25,806)

CONSOLIDATED BALANCE SHEET

	30 Sept	30 Sept
	1999	1998
AS AT	\$'000	\$'000

Δ	C	C	FΊ	Γ C
\rightarrow	٠,	. "	٠. ١	

Direct Investments

Unlisted equity shares 61,601 46,986 Loan investments 3,864 4,044

65,465 51,030

Property and equipment 57 80

NON CURRENT ASSETS

Listed equity shares 4,937 10,331

Receivables 1,820 485

Bonds & other interest bearing securities 0 1,937

Cash 373 243

CURRENT ASSETS 7,130 12,996 TOTAL ASSETS 72,652 64,106

LIABILITIES AND SHAREHOLDERS' EQUITY

Capital and reserves

Share capital 48,496 48,496

Share premium 24,260 24,260 Capital profits reserve 13,741 13,741 Unrealised profit reserve (23,219) (34,923) Realised profit reserve 873 10,287

SHAREHOLDERS' FUNDS 64,151 61,861

Trade and other payables 401 1,245

Loans payable 8,100

CURRENT LIABILITIES 8,501 1,000

TOTAL LIABILITIES AND SHAREHOLDERS' FUNDS 72,652 64,106

CONSOLIDATED CASH FLOW STATEMENT

9 Months to 30 Sept to 30 Sept 1999 1998 \$'000 \$'000

NET CASH FLOW FROM PROFIT 2,260 317

Venture capital loans repaid/(advanced) 683 6,505 Investment in unlisted securities (17,639) (21,249)

Sale of unlisted securities 1,749 0

Investment in bonds and interest bearing securities 1,791 7

Purchase of tangible fixed assets 0 (100)

Investment in listed equity investments (1,299) (12,211) Sale of listed equity investments 5,500 5,010

NET CASH FLOW FROM INVESTING ACTIVITIES (9,215) (22,038)

Loans received 4,200 1,000

NET CASH FLOW FROM FINANCING ACTIVITIES 4,200 1,000

Increase/(Decrease) in cash and cash equivalents (2,755) (20,721)

CASH AND CASH EQUIVALENTS

Balance at 1 January 3,128 20,964 Balance at 30 September. 373 243

INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (2,755) (20,721)

BASIS OF PREPARATION

The accounting policies used in this report are the same as those used in the annual audited financial statements of ORESA Ventures S.A. The above figures, except for comparative full year figures, are unaudited. This interim statement is in compliance with International Accounting Standard 34, Interim Financial Reporting.

A copy of the Annual Report for 1998 may be obtained from ORESA Ventures NV, Building O, Drève Richelle 161, B-1410 Waterloo. Alternatively you can request a copy through our web site www.oresaventures.com

Dates for information

- Preliminary report 1999 25th February 2000
- 1 Quarter results 10th May 2000

ORESA VENTURES

oresa ventures s.a. avenue pasteur, 3, 1-2311 luxembourg oresa ventures s.a. waterloo office park, building o, drève richelle 161 b-1410 waterloo, phone: +32-2-357 55 00, fax: +32-2-357 55 05 www.oresaventures.com